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1. Master in evolving
Antibiotics are extensively used worldwide for treating predominantly gram-neg-
ative bacterial infections and also for treating certain gram-positive infections. While 
the precise mechanism of their bactericidal action is yet to be unraveled, aminoglyco-
sides, for example, act by binding to the RNA component of ribosomes, leading to both 
mistranslation and ultimate inhibition of protein synthesis. The widespread use of 
other major classes of antibiotics has resulted in the emergence of resistant bacteria by 
expediting the course of its evolution [1, 2]. The emergence of resistance to antibiotics 
is of special concern in the treatment of infections, particularly of systemic nature, by 
gram-negative organisms narrowing down the options for antibiotic alternatives. The 
resistance mechanisms displayed by the bacteria can be classified into the following: 
(a) reduced uptake, (b) increased efflux, (c) enzymatic modification of drug, and (d) 
drug target modification. Whereas resistance to streptomycin, the first widely used 
aminoglycoside, is predominantly through mutations in drug targets (mostly in the 
ribosomal protein rpsL and also in rRNA), resistance to other aminoglycosides appears 
to utilize a variety of mechanisms. The question arises, whether antibiotic action 
facilitates the emergence of resistant mutants. For certain other classes of antibiotics 
that induce the bacterial SOS response either by direct DNA damage (e.g., ciprofloxa-
cin) or through indirect means (e.g., ampicillin), it has been shown that the action of 
the antibiotic itself plays a significant role in the emergence of mutations that confer 
resistance. One such mechanism, mistranslation due to defects in the translation appa-
ratus, can promote hypermutagenesis in a phenomenon called translational stress-
induced mutagenesis (TSM) raising the possibility that aminoglycoside exposure, by 
promoting mistranslation, could also elevate mutagenesis. According to the current 
understanding, TSM is mediated by a low-level mistranslational corruption of the 
replicative DNA polymerase leading to episodic hypermutagenesis. Exposure of wild-
type bacterial cells to sublethal concentrations of an antibiotic increases mutagenic 
translesion DNA synthesis in vivo, and exposure of certain mutants also increases 
spontaneous mutagenesis. Exposure of wild-type Pseudomonas aeruginosa PAO1 cells to 
sublethal concentrations of tobramycin and amikacin, two aminoglycoside antibiotics 
commonly used to treat P. aeruginosa infections, can elevate spontaneous mutagenesis 
leading to complications in treating cystic fibrosis patients [3].
2. Master in dominating
Cystic fibrosis (CF) is an autosomal recessive genetic condition among 
Caucasians, with an incidence rate of 1 in 2500 live births. The morbidity and 
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mortality associated with this disease condition are due to thickened lung secretions 
and subsequent creation of hypoxia and secondary infections predominantly by 
opportunistic pathogens. Bacteria such as Pseudomonas aeruginosa, Staphylococcus 
aureus, and Burkholderia cepacia complex have been in the limelight as the patho-
gens that affect CF patients with progression of lung disease ultimately leading 
to mortality. Interestingly, recent developments in high-throughput genomic 
techniques revealed the presence of several other bacterial species, which were 
hardly identified using conventional microbiological techniques. Enteric bacteria, 
such as Prevotella, Bacteroides, Fusobacterium, Mycoplasma, Ralstonia, Veillonella, 
etc., which do not normally appear in the laboratory cultures were identified and 
were found to have an impact on the CF microbiome [4]. This fluctuation in the 
CF microbiome may be due to transition of atypical species toward chronic mode 
of infection through formation of biofilms, dormancy, small colony variants, etc. 
The immunocompromised nature of CF patients predisposes them to a variety of 
infections, thereby increasing the need for antibiotics, alone or in combination, on a 
daily basis, at milligram levels. Such a continuous antibiotic pressure drives evolu-
tion of lung pathogens through the downregulation of acute-mode virulence factors 
in order to avoid unnecessary energy loss and expression of regulons associated 
with chronic mode of infection/colonization. Though the CF microbiome has been 
shown to consist of several species of bacteria, P. aeruginosa becomes the pre-
dominating one during the course of chronic colonization in the CF lung, thereby 
increasing its significance when considering appropriate treatment strategy [5].
Apart from the abovementioned bacterial species in the CF microbiome, myco-
bacteria, in general, are widespread organisms except tuberculosis (Mycobacterium 
tuberculosis) and leprosy (M. leprae) pathogens which are obligate parasites always 
in need of a host. These bacteria are often involved in asymptomatic infections, are 
highly fastidious organisms showing resistance to antibiotics, and are able to sur-
vive for long periods in acids, alkali, detergents, etc. Non-tuberculous mycobacteria 
constitute all the other mycobacteria gaining importance in respiratory infections 
including the one resembling tuberculosis. Practically, overgrowth of pseudo-
monads and other predominant bacterial species in the lung makes it difficult to 
understand the existence of atypical bacteria in the case of CF lung infections. The 
inherent slow growth rate of mycobacteria adds to failures in preliminary detec-
tion of these bacteria. Once identified it requires a prolonged treatment regime for 
several months with combined antibiotics, which add stress to the CF lung environ-
ment, thereby resulting in a progressive deterioration of lung function with conse-
quent emergence of resistant pathogens. Dominance by P. aeruginosa or few known 
predominant bacterial species in the CF lung is clinically beneficial in the sense that 
these outnumbered species may offer protection against more pathogenic species 
such as mycobacteria [6].
3. A friend or a foe?
Normally, tuberculosis is rare among CF patients, and it was found to complicate 
the CF disease condition. It is also interesting to know that the CF disease condition 
will not support growth of TB mycobacteria (Mycobacterium tuberculosis) and the 
risk of TB in these patients is high in areas with high prevalence. In addition, other 
chronic illnesses such as poorly controlled diabetes were considered as an additional 
risk factor among CF patients.
Among non-typical mycobacteria (NTM), M. abscessus is considered the most 
clinically virulent species. Isolation of NTM is common in CF patients before 
lung transplantation as revealed by data from a large US center. However, reports 
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mention high variability in infection rates predominantly with single species and 
rarely by two mycobacteria due to several factors from diversity in methodology, 
number of patients involved in the studies, geographical and racial differences, 
and the age factor, with some ambiguity in the case of gender basis. Adolescents 
and young adults (10–25 years age) are prone to NTM infections with rapidly 
growing strains infecting patients of all age groups. The slow-growing species 
M. avium, M. intracellulare, and other genetically related species are prevalent 
in North America, whereas the rapidly growing M. abscessus prevails in Western 
Europe and Israel. Infrequent prevalence was reported for M. fortuitum, M. 
gordonae, M. kansasii, M. simiae, M. peregrinum, and M. malmoense [7]. However, 
survival of CF patients infected with NTM before transplantation is reported 
to be similar to that of patients without NTM infection. Overall, the predomi-
nance of P. aeruginosa could help keep a check on infections by other pathogenic 
bacteria [8].
4. The concern
Huge genetic repertoire and mosaic genome structure of P. aeruginosa make it a 
versatile opportunistic pathogen in nosocomial settings, particularly in conditions 
involving burns and wounds, meningitis, endocarditis, and microbial keratitis. 
Interestingly, P. aeruginosa displays a common phenotype in the CF lung irrespective 
of the genetic content, which includes mucoidy, lipopolysaccharide modifications, 
lack of flagella and pili, upregulated antibiotic efflux, etc. New forms of emerging 
resistance in bacteria spread rapidly by intra- and interspecies acquisition of genetic 
content from the environment where community biofilms are common. In addition 
to being a threat to public health, highest resistance rates correlate with highest per 
capita antibiotic consumption of a nation.
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